Palifermin. Prevention of oral mucositis: Inappropriate evaluation

Prescrire International

Volumn 16, Issue 90, 2007, Pages 135-138

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; HEPARIN; MELPHALAN; PALIFERMIN; PLACEBO; ICE; KERATINOCYTE GROWTH FACTOR;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ACUTE LEUKEMIA; ACUTE PANCREATITIS; ARTICLE; BASAL CELL CARCINOMA; BLURRED VISION; BURNING SENSATION; CATARACT; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; COST OF ILLNESS; CRYOTHERAPY; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; ENZYME ACTIVITY; ERYTHEMA; EUROPE; EYE IRRITATION; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; INTERMETHOD COMPARISON; LEUKEMIA; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; MYELOMA; NEPHROTOXICITY; NONHUMAN; ORAL MUCOSAL DISEASE; OUTCOME ASSESSMENT; PAIN; PANCREAS DISEASE; PROTEINURIA; PRURITUS; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RISK ASSESSMENT; SENSORY DYSFUNCTION; SIDE EFFECT; SKIN CANCER; SKIN EDEMA; STEM CELL TRANSPLANTATION; TASTE DISORDER; TONGUE; WHOLE BODY RADIATION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FRANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MOUTH MUCOSA; PATHOLOGY; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SKIN; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CRYOTHERAPY; FIBROBLAST GROWTH FACTOR 7; FRANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ICE; MOUTH MUCOSA; MUCOSITIS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS; SKIN; TREATMENT OUTCOME;

EID: 34547901095     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. "Lymphomas". in: "Martindale The complete drug reference" The Pharmaceutical Press, London. Website www.medicinescomplete.com accessed 27 December 2006: 16 pages.
2. "Leukaemias, chronic". In: "Martindale The Complete Drug Reference" The Pharmaceutical Press, London. Website www.medicinescomplete.com accessed 27 December 2006: 10 pages.
3. Prescrire Rédaction "Les lymphomes non Hodgkiniens. La malignité varie beaucoup selon les cas" Rev Prescrire 2003; 23 (237):209-214.
4. Prescrire Rédaction "Myélome multiple. Idées Forces Prescrire" Updated in April 2006; www.prescrire.org: 7 pages.
5. European Medicines Agency - CHMP "European Public Assessment Report (rev. 1) - Kepivance. Scientific discussion"; 55 pages: posted on the EMEA website on 8 August 2006.
6. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Application number: BLA 125103/0. Medical review" 30 November 2004: 295 pages.
7. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Application number: BLA 125103/0. Statistical review" 2 December 2004: 60 pages.
8. Haute autorité de santé - Commission de la transparence "Avis de la Commission Kepivance" 15 February 2006: 9 pages.
9. Stiff PJ et al. "Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting" J Clin Oncol 2006; 24 (4): 1-8.
10. Spielberger R et al. "Palifermin for oral mucositis after intensive therapy for hematologic cancers" N Engl J Med 2004, 351 (25): 2590-2598 +(letters) 352 (12): 1264-1265.
11. Blazar BR et al. "Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT)" Blood 2006; 108 (9): 3216-3222.
12. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Postmarketing study commitments". Website www.fda.gov accessed 29 November 2005: 5 pages.